Core Viewpoint - Baiyunshan Pharmaceutical Group's stock performance shows a slight increase, with significant financing activities indicating high investor interest and potential volatility in the market [1][2]. Financing Activities - On October 27, Baiyunshan had a financing buy-in amount of 26.22 million yuan and a financing repayment of 30.97 million yuan, resulting in a net financing outflow of 4.76 million yuan [1]. - The total financing and securities lending balance for Baiyunshan reached 949 million yuan, with the financing balance accounting for 2.62% of the circulating market value, indicating a high level compared to the past year [1]. Securities Lending - On the same day, Baiyunshan repaid 8,000 shares in securities lending, with no shares sold, resulting in a securities lending balance of 2.25 million yuan, which is also at a high level compared to the past year [1]. Company Overview - Baiyunshan, established on September 1, 1997, and listed on February 6, 2001, operates in various sectors including traditional Chinese medicine, chemical raw materials, and health management services [2]. - The company's revenue composition includes 69.32% from large commercial operations, 16.79% from health products, and 12.53% from traditional Chinese medicine [2]. Financial Performance - For the first half of 2025, Baiyunshan reported a revenue of 41.84 billion yuan, reflecting a year-on-year growth of 1.93%, while the net profit attributable to shareholders was 2.52 billion yuan, showing a decrease of 1.31% [2]. Dividend Distribution - Since its A-share listing, Baiyunshan has distributed a total of 10.91 billion yuan in dividends, with 4.36 billion yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders of Baiyunshan include significant institutional investors, with Hong Kong Central Clearing Limited being the fifth largest shareholder, increasing its holdings by 9.36 million shares [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 補充公告 須予披露交易 收購目標公司11.04%股權 廣州白雲山醫藥集團股份有限公司 茲提述廣州白雲山醫藥集團股份有限公司（「本公司」）日期為2025年9月28日之公告（「該公告」），內容 有關收購目標公司11.04%股權之須予披露交易。除文義另有所指外，本公告所採用之詞彙與該公告 所界定者具有相同涵義。 董事會謹此向本公司股東及潛在投資者提供有關收購事項之補充資料如下： 關於目標公司及目標股份對應的所有者權益賬面價值 根據目標公司按照中國企業會計準則編製的截至2024年12月31日止財政年度的經審核綜合財務報 表，及截至2025年6月30日未經審核綜合財務報表，目標股份的賬面價值載列如下： | | 截至2024年 | 截至2025年 | | --- | --- | --- | | 項目 | 12月31日止 | 6月30日止 | | | （人民幣元） | （人民幣元） | | 目標公司所有者權益賬面價值 ...

關於目標公司及目標股份對應的所有者權益賬面價值 根據目標公司按照中國企業會計準則編製的截至2024年12月31日止財政年度的經審核綜合財務報 表，及截至2025年6月30日未經審核綜合財務報表，目標股份的賬面價值載列如下： | | 截至2024年 | 截至2025年 | | --- | --- | --- | | 項目 | 12月31日止 | 6月30日止 | | | （人民幣元） | （人民幣元） | | 目標公司所有者權益賬面價值 | 7,787,898,114.01 | 7,853,994,659.66 | | 目標股份對應的所有者權益賬面價值 | 859,783,951.79 | 867,081,010.43 | 1 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 補充公告 須予披露交易 收購目標公司11.04%股權 茲提述廣州白雲山醫藥集團股份有限公司（「本公司」）日期為2025年9月28日之公告（「該公告」），內容 有關收購目標公司11. ...

京东健康CEO曹冬表示，广药集团是京东健康最重要的战略伙伴之一，希望未来能够更好地将广药的优 质产品与京东健康的数字能力、服务场景紧密结合，挖掘新的增长机会，共同为更多用户提供优质的健 康服务。 据悉，自2017年开启深度合作以来，广药集团与京东健康始终秉持互信共赢的理念，合作成果丰硕，过 去三年双方合作业务更是保持了20%以上的高复合增长，为此次战略升级奠定了坚实基础。 就合作项目的落地，广药集团党委副书记、副董事长、总经理陈杰辉表示，接下来双方构建常态化全层 级协同机制，决策层引领、执行层推进、业务层联动；深化优势互补，聚焦大品种拓展等领域突破；拓 展创新边界，共探出海等新场景合作，力争今年合作业务大幅增长，明年向更高目标迈进。 本报讯(记者王镜茹)10月21日，广州医药集团有限公司(以下简称"广药集团")与京东健康在广州签署战 略合作协议。 根据合作协议，双方将以数智创新为核心引擎，整合产品、渠道、技术和服务资源，围绕供应链协同、 市场运营、用户服务等维度，构建多层次、一体化的合作体系，推动资源高效整合与价值释放，为消费 者提供更高效、便捷的健康产品与服务体验。 广药集团党委书记、董事长李小军表示，此次 ...

Core Viewpoint - The announcement indicates that Guangzhou Wanglaoji Pharmaceutical Co., Ltd., a subsidiary of Baiyunshan, has officially launched a Phase III clinical trial for the treatment of acute pharyngitis with the product "Keganli Yan Koufuye" [2] Group 1 - The Phase III clinical trial aims to evaluate the efficacy and safety of Keganli Yan Koufuye in treating acute pharyngitis, specifically for the external wind-heat syndrome [2] - The initiation of this clinical trial marks a significant step in the development of the product, potentially leading to its market introduction [2]

Core Viewpoint - Baiyunshan announced the initiation of a Phase III clinical trial for its product, Keguan Liyan Oral Solution, aimed at treating acute pharyngitis [1] Group 1: Company Information - Baiyunshan's subsidiary, Guangzhou Wanglaoji Pharmaceutical Co., Ltd., held a launch meeting for the Phase III clinical trial of Keguan Liyan Oral Solution [1] - Keguan Liyan Oral Solution received its new drug certificate and production approval in 1997, indicating its long-standing presence in the market [1] - The product is designed to relieve symptoms associated with wind-heat invasion and is primarily used for colds with external wind-heat and internal heat disturbance [1] Group 2: Clinical Trial Details - The Phase III clinical trial was approved by the National Medical Products Administration in February 2024, allowing for confirmatory clinical trials for acute pharyngitis [1] - The trial aims to validate the efficacy of Keguan Liyan Oral Solution in treating acute pharyngitis, which is categorized under the wind-heat syndrome [1]

Core Viewpoint - The company has officially launched a Phase III clinical trial for its proprietary product, Keguan Liyan Oral Solution, aimed at treating acute pharyngitis caused by external wind-heat syndrome [1] Group 1: Product Information - Keguan Liyan Oral Solution received its new drug certificate and production approval in 1997, making it a unique product of Wanglaoji Pharmaceutical [1] - The product is included in the 2025 edition of the Pharmacopoeia of the People's Republic of China and is known for its effects of dispelling wind, clearing heat, and detoxifying, primarily used for colds associated with external wind-heat invasion [1] Group 2: Clinical Trial Details - Wanglaoji Pharmaceutical obtained the clinical trial approval notice from the National Medical Products Administration in February 2024, allowing the company to conduct confirmatory clinical trials for acute pharyngitis [1] - The Phase III clinical trial has recently been officially initiated by Wanglaoji Pharmaceutical [1]

Core Viewpoint - The company announced the initiation of a Phase III clinical trial for its product, Keguanli Yan Oral Liquid, aimed at treating acute pharyngitis associated with external wind-heat syndrome [1] Group 1 - The clinical trial was organized by the company's subsidiary, Guangzhou Wanglaoji Pharmaceutical Co., Ltd. [1] - The trial is a significant step in the development of the company's product portfolio in the pharmaceutical sector [1]

Core Viewpoint - The company announced the initiation of a Phase III clinical trial for its proprietary product, Keguanli Yan Oral Liquid, aimed at treating acute pharyngitis caused by external wind-heat syndrome [1] Group 1: Product Information - Keguanli Yan Oral Liquid received its new drug certificate and production approval in 1997, making it a unique product of Wanglaoji Pharmaceutical [1] - The product is included in the 2025 edition of the Pharmacopoeia of the People's Republic of China and is known for its effects of dispelling wind, clearing heat, and detoxifying, primarily used for cold symptoms associated with wind-heat invasion [1] Group 2: Clinical Trial Details - Wanglaoji Pharmaceutical obtained the clinical trial approval notice from the National Medical Products Administration in February 2024, allowing the company to conduct confirmatory clinical trials for acute pharyngitis [1] - The Phase III clinical trial has recently been officially launched by Wanglaoji Pharmaceutical [1]

关于子公司药物进入 III 期临床试验的公告 证券代码：600332 证券简称：白云山 公告编号：2025－076 广州白云山医药集团股份有限公司 王老吉药业2024年克感利咽口服液的销售额为人民币1,828.52万元，除王老吉药 业生产的克感利咽口服液外，中国境内上市的克感利咽颗粒的生产厂家有葵花药业集 1 团（襄阳）隆中有限公司、临江市宏大药业有限公司等。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"公司"）子公司广州王老吉药业股份有限 公司（"王老吉药业"）于近日召开克感利咽口服液治疗急性咽炎（外感风热证）的 III期临床试验启动会，该III期临床试验项目正式启动。现将相关情况公告如下： 一、克感利咽口服液的基本情况 药物名称：克感利咽口服液 剂型：合剂 规格：10 mL/支 注册分类：2.3类新药 二、克感利咽口服液的其他情况 克感利咽口服液于1997年获得新药证书和生产批件，是王老吉药业独家品种，收 载于《中华人民共和国药典》2025年版一部，具有疏风清热，解毒利咽作用，主要用 ...